Date: Jan 07, 2014 Author: press release Source: Business Wire (
click here to go to the source)
SAN FRANCISCO--(BUSINESS WIRE)--Gemmus, a privately-held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases, announced today that the company has entered into an agreement with Woodside Capital Partners, retaining them as the company’s advisor and investment bank.
“Gemmus is pleased to begin working with Woodside Capital Partners as we move forward with strategic plans for our novel candidate flu treatment (GP1681),” said Daryl Faulds, Ph.D., CEO and Co-founder of Gemmus. “The team at Woodside Capital has a strong track record providing superior M&A advice to promising companies such as Gemmus.”
“As Gemmus is preparing to move into the clinic with GP1681, our host-directed treatment for flu, the time is right to retain an investment bank,” said William Guilford, President and Co-founder of Gemmus Pharma. “We are looking forward to working with Woodside Capital Partners to help the company achieve our near and long-term goals.”
“Woodside Capital looks forward to teaming with the experienced management group and board at Gemmus to determine the best strategic option for GP1681,” said John Selig, Managing Director and co-head of Woodside Capital’s Healthcare Group. “This therapy works by modulating the host response of the patient, in contrast to typical treatments that focus on attacking a specific virus. We believe it holds enormous promise as a first-in-class therapeutic for influenza, where there is a significant need for a broadly effective, strain-agnostic solution.”
About Gemmus Pharma
Gemmus is a privately-held biotechnology company developing innovative pharmaceutical products for the treatment of infectious diseases by focusing on modulating the host response to disease. Gemmus was founded in 2007 to develop novel treatments for influenza based on EP2 and EP4 agonists, and in-licensed technology from a major pharmaceutical company. Gemmus has received SBIR (NIH) and QTDP competitive grants and is funded by a syndicate of angel groups led by the Life Science Angels (LSA). Gemmus is a member of the QB3 network, a San Francisco Bay Area Biotech incubator associated with UCSF Mission Bay campus. For more information and corporate background, please visit: www.gemmuspharma.com.
About Woodside Capital Partners
Woodside Capital Partners is a global, independent investment bank that delivers world-class strategic and financial advice to emerging growth companies in the life sciences and technology sectors. With a strong track record in M&A, strategic partnerships and private placements, Woodside Capital Partners has been providing worldwide investment banking services since 2001 with leading domain experience in healthcare, software, Internet services, electronic communications and materials. The team of Woodside Capital Partners has completed transactions totaling more than $10 billion. Woodside Capital Partners is the Silicon Valley headquarters of M&A International, the world’s leading mergers and acquisitions alliance. Securities offered through Woodside Capital Securities LLC, member FINRA/SIPC. For more information, please visit www.woodsidecap.com.
Gemmus Pharma Inc
Daryl Faulds Ph.D., 415-978-2151